Reversal of anticancer drug resistance by COTC based on intracellular glutathione and glyoxalase I.
Suppression of resistance to anticancer drugs by COTC of glyoxalase I (GloI) inhibitor targeting intracellular glutathione (GSH) and GloI was studied. Depletion of the cellular GSH content and inhibition of GloI by COTC increased chemotherapy-mediated apoptosis in apoptosis-resistant pancreatic adenocarcinoma AsPC-1 cells.
Kamiya
Daisuke
D
Graduate School of Science and Technology, Keio University, Hiyoshi, Yokohama 223-8522, Japan.
Uchihata
Yuki
Y
Ichikawa
Eiko
E
Kato
Kuniki
K
Umezawa
Kazuo
K
D000970:Antineoplastic Agents / Q000737:chemistry / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects; D045744:Cell Line, Tumor; D003512:Cyclohexanones / Q000737:chemistry* / Q000494:pharmacology; D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D005978:Glutathione / Q000037:antagonists & inhibitors*; D006801:Humans; D007791:Lactoylglutathione Lyase / Q000037:antagonists & inhibitors*; D010190:Pancreatic Neoplasms / Q000473:pathology; D013329:Structure-Activity Relationship
D000970:Antineoplastic Agents; D003512:Cyclohexanones; C011202:2-crotonyloxymethyl-(4R,5R,6R)-4,5,6-trihydroxycyclohex- 2-enone; D007791:Lactoylglutathione Lyase; D005978:Glutathione